NEW YORK (GenomeWeb News) — Invitrogen today said it has closed its acquisition of Sentigen Holding.
The $25.9 million cash deal was announced in September.
Invitrogen paid $3.37 per share for the Phillipsburg, NJ-based company, which will become part of Invitrogen’s Discovery Sciences division, located in Madison, Wis.
With the acquisition, Invitrogen picks up Sentigen’s Tango assay system for protein interaction and GPCR screening and its assay ready cells that pare down the assay process, the company said.
At close of the business day Dec. 1, Sentigen had $11 million in cash on hand and cash investments, the company said. At mid-day today Sentigen shares were trading at $3.40.